1 **Severe COVID-19 and Diabetes – A Retrospective Cohort Study from Three London**

2 **Teaching Hospitals**

3 Chioma Izzi-Engbeaya^{a,1,2,3} (ORCID ID 0000-0001-7599-0166), Walter Distaso^{a,4}, Anjali
 4 Amin^{1,2}, Wei Yang^{2,5}, Oluwagbemiga Idowu^{1,2}, Julia S Kenkre^{2,5} (ORCID ID 0000-0001-
 5 7505-4319), Ronak J Shah¹, Evelina Woin¹, Christine Shi¹, Nael Alavi^{1,2}, Hala Bedri¹,
 6 Niamh Brady¹, Sophie Blackburn^{1,2}, Martina Leczycka^{1,2}, Sanya Patel^{1,2}, Elizaveta Sokol^{1,2},
 7 Edward Toke-Bjolgerud^{1,2}, Ambreen Qayum^{1,2}, Mariana Abdel-Malek^{2,5}, David C D
 8 Hope^{1,2,3}, Nick S Oliver^{1,2,3}, Vasiliki Bravis^{1,2}, Shivani Misra^{1,2,3}, Tricia M Tan^{1,2,3,5}, Neil
 9 Hill^{b,1,2,3}, Victoria Salem^{* b,1,2,3} (ORCID ID 0000-0001-6463-7471)

10 ^aJoint first authors; ^bJoint senior authors

11 ¹Division of Medicine and Integrated Care, Imperial College Healthcare NHS Trust, London,
 12 UK

13 ²Imperial Centre for Endocrinology, Imperial College Healthcare NHS Trust, London, UK

14 ³Section of Investigative Medicine and Endocrinology, Department of Metabolism, Digestion
 15 and Reproduction, Imperial College London, UK

16 ⁴Imperial College London Business School, London, UK

17 ⁵Department of Clinical Biochemistry, Imperial College Healthcare NHS Trust, London, UK

18 **Correspondence to:**

19 Dr Victoria Salem,
 20 Section of Endocrinology and Investigative Medicine,
 21 Division of Diabetes, Endocrinology and Metabolism,
 22 Department of Medicine,
 23 Imperial College London,
 24 London, W12 0NN, UK.

25 +44 (0)20 7594 2489

26 v.salem@imperial.ac.uk

27 **ABSTRACT**

28 Patients with diabetes mellitus admitted to hospital with COVID-19 caused by infection with
 29 the novel coronavirus (SARS-CoV-2) have poorer outcomes. However, the drivers for this
 30 are not fully elucidated. We performed a retrospective cohort study, including detailed pre-
 31 hospital and presenting clinical and biochemical factors of 889 patients diagnosed with
 32 COVID-19 in three constituent hospitals of a large London NHS Trust. 62% of patients with
 33 severe COVID-19 were of non-White ethnic backgrounds and the prevalence of diabetes
 34 was 38%. 323 (36%) patients met the primary outcome of death or admission to the
 35 intensive care unit (ICU) within 30 days of diagnosis. Male gender, advancing age and the
 36 Clinical Frailty Scale, an established measure of multimorbidity, independently predicted
 37 poor outcomes on multivariate analysis. Diabetes did not confer an independent risk for
 38 adverse outcomes in COVID-19, although patients with diabetes and ischaemic heart
 39 disease were at particular risk. Additional risk factors which significantly and independently
 40 associated with poorer outcomes in patients with diabetes were age, male gender and
 41 lower platelet count. Antiplatelet medication was associated with a lower risk of death/ICU
 42 admission and should be evaluated in randomised clinical trials amongst high risk patient
 43 groups.

44 Introduction

45 The World Health Organisation (WHO) announced a global pandemic of COVID-19 Severe
46 Acute Respiratory Syndrome (SARS) caused by the novel coronavirus (SARS-CoV-2) on
47 11th March 2020. Wide-ranging restrictions aimed at reducing spread of the virus
48 (“lockdown measures”) were introduced in the United Kingdom (UK) on 23rd March 2020.
49 Around this time, London hospitals experienced the first surge of cases. By late June in the
50 UK (28th June 2020), there were 311,151 confirmed cases and 43,550 deaths. On 7th July
51 2020, the UK Office for National Statistics reported that excess deaths had fallen below the
52 5-year average for the second consecutive week since the coronavirus pandemic was
53 announced¹, marking the end of the first wave of infections in England. However, there
54 remain local areas of increasing infection rates across the country and a risk of future
55 upsurges². Therefore, understanding clinical correlates with disease severity, from the
56 point of view of hospital triaging and advice on shielding, remains of paramount importance.

57 In February 2020, the first cohort studies from Wuhan were reporting clinical outcomes of
58 patients treated for COVID-19³⁻⁷. These earliest studies reported age and male gender as
59 major risk factors for poorer outcomes. Patients with comorbidities, most commonly
60 hypertension and ischaemic heart disease, were over-represented in hospital or intensive
61 care unit (ICU) admissions^{3,5,6}, although it was not immediately clear to what extent these
62 were independent of advancing age.

63 Early on it was noted that the prevalence of diabetes in patients admitted to ICU for severe
64 COVID-19 (typically 20-30%^{5,7}) was much greater than the adult population prevalence,
65 which is 6.8% in the UK⁸. Patients infected with the prior two established human
66 coronavirus infections (SARS-CoV and Middle East Respiratory Syndrome, MERS-CoV)
67 were more likely to experience more severe disease and die if they had a diagnosis of
68 diabetes^{9,10}. However, granularity on the way diabetes interacts with the natural history of
69 COVID-19 has been slower to come and remains an area of intense concern for patients
70 with diabetes¹¹ and their healthcare providers.

71 Two major hospital cohort studies have provided some insight about the interaction
 72 between diabetes and COVID-19. Zhu et al concluded that good glycaemic control in the
 73 acute hospital setting in China was an important factor for better outcomes in patients with
 74 pre-existing type 2 diabetes, although it was difficult to ascertain whether this was
 75 confounded by the possibility that poorer glycaemia in hospital was itself a marker of a
 76 more severe inflammatory response or the decision to use corticosteroids¹². In Europe, a
 77 French consortium published a multicentre observational study (CORONADO) looking at
 78 clinical features associated with disease severity in people with diabetes hospitalised for
 79 COVID-19. The CORONADO study reported that on multivariate analysis of patients with
 80 diabetes hospitalised for COVID-19, BMI, but not glycated haemoglobin (HbA1C), was
 81 positively and independently associated with poorer outcomes¹³.

82 Here we report on all patients treated as an inpatient for swab-positive COVID-19 in three
 83 West London teaching hospitals, under the umbrella of Imperial College Healthcare NHS
 84 Trust (ICHNT), during our peak period of infections. We focus on clinical and biochemical
 85 features associated with COVID-19 disease severity within the whole cohort as well as the
 86 subset of patients with a diagnosis of diabetes. Our data suggest that it is age and its
 87 implicit association with multimorbidity that predicts poorer outcome, with the Clinical Frailty
 88 Scale (CFS) being a good measure of this. Patients with diabetes are at risk of more
 89 severe coronavirus infection because of increased association with other medical
 90 conditions, particularly ischaemic heart disease.

91 Results

92 STUDY COHORT

93 We report on 889 consecutive adult patients with a confirmed (SARS-CoV-2 swab positive)
 94 diagnosis of COVID-19 admitted to three Central London hospitals within the same NHS
 95 Trust (ICHNT) between 6th March 2020 and 22nd April 2020. A total of 323 (36%) of these
 96 patients met the primary outcome of death or admission to the intensive care unit (ICU)
 97 within 30 days of diagnosis. A total of 110 patients were admitted to ICU, of which 101
 98 required endotracheal intubation and 50 of these ICU-admitted patients died. In the cohort
 99 of patients studied here, 337/889 (38%) had a diagnosis of diabetes, 96% (324/337) of
 100 people with diabetes had Type 2 diabetes (including 4 patients who were diagnosed during
 101 their admission for COVID-19) and the remainder (13 patients) had Type 1 diabetes. The
 102 Study Flow Diagram is shown in Figure 1.

103 FACTORS PRIOR TO HOSPITAL ADMISSION

104 The characteristics of the entire cohort are shown in Table 1. Of all patients treated for
 105 COVID-19 in our NHS Trust, the average ($\pm$ SD) age was 65.8 ($\pm$ 17.5) years and 60% were
 106 men. The average ($\pm$ SD) weight for men was 80.8 ($\pm$ 19.8) kg and for women 72.6 ($\pm$ 24.2)
 107 kg.

108 62% of our cohort were from non-White ethnic backgrounds, including 17% Black and 11%
 109 South Asian. The commonest co-morbidities were hypertension (47%),
 110 hypercholesterolaemia (43%), diabetes (38%) and ischaemic heart disease (IHD, 16%).

111 By comparison, amongst the patients treated for COVID-19 who had diabetes, the average
 112 age was 68.5 $\pm$ 14.6 years and 66% were men. Average weight was 83.5 ($\pm$ 18.9) kg for
 113 men and 77.8 ($\pm$ 24.5) kg for women. In this cohort of patients with diabetes, 72% were
 114 non-White, including 20% Black and 14% South Asian; and a past medical history of
 115 hypertension was present in 70%, IHD in 28% and hyperlipidaemia in 51%. The use of

glucose lowering medications in this population at the time of diagnosis of COVID-19 is summarised in Table 1. Average HbA1C was 64.7 ($\pm$ 21.7) mmol/mol (8%), 27% were taking an angiotensin converting enzyme (ACE) inhibitor and 63% were taking a statin.

FACTORS AT THE TIME OF DIAGNOSIS OF COVID-19

Table 2 summarises the differences in biochemical measurements and clinical measurements between patients who fulfilled the primary outcome compared with patients who survived and were not admitted to ICU; and between patients with a diagnosis of diabetes and those without diabetes. As expected, biochemical parameters established to be associated with severe infection were significantly higher in the group who fulfilled the primary outcome of death/ICU admission, including C-reactive protein (CRP), d-dimers, procalcitonin, brain natriuretic peptide (BNP) and ferritin. For both patients with diabetes and those without, a capillary blood glucose (CBG) below 10 mmol/L at presentation was associated with a lower risk of poor outcome. In the cohort without diabetes, this association was sustained after correction for age and gender as described elsewhere¹⁴, however this was not sustained on multivariate analysis in our cohort (see below).

Amongst patients with diabetes, those with more severe infection had significantly lower arterial blood gas pH values, lower bicarbonate levels and higher serum potassium levels (although still, on average, within the laboratory reference range) at the time of COVID-19 diagnosis. This hints at the possibility that patients in the primary outcome group were more likely to have diabetic metabolic emergencies at presentation, similar to what has been reported by other groups^{15,16}. Indeed, in our cohort there were 59 episodes of diabetic ketoacidosis (DKA) associated with COVID-19 during the data collection period.

Chest radiographs on diagnosis were reported by in-house radiologists on a five-point severity scale (1 = normal, 5 = widespread, dense bilateral infiltrates). 60% of patients who survived without ICU admission had classic patchy ground glass changes, with a median

severity score of 2 out of 5. Amongst those who died/were admitted to ICU, 72% had classic radiological features with a median severity score of 3. These proportions were similar amongst the patients with diabetes.

CLINICAL FEATURES IN THE WHOLE COHORT ASSOCIATED WITH THE PRIMARY OUTCOME (DEATH OR ICU ADMISSION WITHIN 30 DAYS OF COVID-19 DIAGNOSIS)

On univariate analysis, the risk of the primary outcome (death or ICU admission within 30 days of COVID-19 diagnosis) was significantly higher in men and older age groups (Table 1). Several co-morbidities (i.e. hypertension, ischaemic heart disease and heart failure) were also associated with an increased risk of poor outcome. Patients taking an ACE inhibitor had an odds ratio of 1.57 (CI 1.10 to 2.22, $p=0.013$) for the primary outcome, but an increased risk was not statistically evident with patients on angiotensin receptor blocker (ARB) drugs. The Clinical Frailty Scale (CFS) is widely used in the UK and scores range from 1 (very fit) to 9 (terminally ill)¹⁷. Here we show that the CFS was a good predictor of poorer outcomes, with patients scoring ≥ 7 having an odds ratio of 2.34 (1.46 to 3.76, $p=0.0004$) for death/ICU admission compared with those scoring 1-2. Similarly, an estimated glomerular filtration rate (eGFR) at the time of COVID-19 diagnosis of <45 mL/min was associated with a 3 to 4-fold increased risk of death/ICU admission. Weight >80 kg did not reach significance for predicting poorer outcomes.

After removing datasets where $>5\%$ datapoints were missing (i.e. 170 patients), we ran an unselected multivariate logistic regression analysis of 37 regressors (variables) against the primary outcome on 719 patients (Table 3). Age and gender retained significance as independent variables. As well as reporting p-values for the significance of the independent contribution of a given variable, we have also calculated marginal effect sizes. This percentage value is a measure of the altered risk of primary outcome (death/ICU admission) as the given variable changes. The marginal effect of male gender was +9.3%, i.e. all other factors being the same, the risk of primary outcome was 9.3% higher for men

than women. The CFS was also found to be a significant independent predictor of death/ICU admission. Each unit rise in score (from 1-9) was associated with a 3.1% increased risk of death/ICU admission, all other things being equal.

The association between ethnicity and poor outcome was not sustained on multivariate analysis in our cohort. None of the individual co-morbidities we collected data on (i.e. diabetes, hypertension, hyperlipidaemia, IHD, cerebrovascular disease, heart failure, chronic obstructive airway disease (COPD) and cancer) were found to be independent predictors of mortality/ICU admission in this analysis, including diabetes.

Taking an antiplatelet drug was significantly and independently associated with a 10% lower risk of death and/or ICU admission (Table 3). Related to this, platelet count was a significant predictor of poor outcome. Our data suggest that every reduction in platelet count of $100 \times 10^9/L$ is associated with a 10% risk of death/ICU admission. This association remained after removal of patients with platelet counts below $50 \times 10^9/L$ (the majority of whom had active, often haematological, malignancies). Higher serum sodium at the time of COVID-19 diagnosis was also found to be a strong independent predictor of poor outcome, however this association disappeared after removing patients with high sodium (i.e. >145 mmol/L). As a sensitivity analysis, we performed a regularised regression (Smoothly Clipped Absolute Deviation - SCAD)¹⁸⁻²⁰, which selects the truly significant variables in the multivariate regression without the limitations of a stepwise approach (see Supplementary Methods). This SCAD analysis identified 23 variables driving the variance. It supported the findings of the unrestricted multivariate regression (Supplementary Table 1).

CLINICAL FEATURES IN PATIENTS WITH DIABETES MELLITUS ASSOCIATED WITH THE PRIMARY OUTCOME

Unrestricted multivariate logistic analysis with $>95\%$ complete datasets was possible on 278 patients with diabetes (Table 4). This excluded HbA1C from the analysis due to

inadequate data. However, multivariate analysis on 197 patients for HbA1C did not produce a significant interaction with the primary outcome ($p>0.9$) and neither was it a significant factor on univariate analysis (Table 1). On the unrestricted multivariate analysis of patients with diabetes, no medication type was significantly associated with poorer outcomes. Of all the associated co-morbidities examined, ischaemic heart disease had a highly significant 33% marginal effect for increased likelihood of death/ICU admission. Other factors significantly and independently associated with poor outcome in patients with diabetes were age, male gender and lower platelet count (Table 4). This was corroborated on SCAD analysis (Supplementary Table 2)

STRATIFIED MARGINAL EFFECT SIZE FOR THE SIGNIFICANT PREDICTORS THAT SURVIVED MULTIPLE LOGISTIC REGRESSION: PLATELET COUNT AND THE CLINICAL FRAILTY SCALE (CFS)

It has been suggested that the CFS is a reasonable measure to include in decision-making tools for escalation to ICU care²¹. However, it was developed for use in people aged >65 years¹⁷, and has not been validated in the general population as a tool for guiding escalation decisions. Therefore, we stratified the marginal effect of the CFS score as an independent predictor of poor outcome in COVID-19 by age group (Figure 2a). This confirms that the CFS is a useful predictor of primary outcome in older age groups. Similarly, the independent marginal effect of platelet count tends to increase with age (Figure 2b) but there was no interaction with the use of antiplatelet drugs ($p>0.9$).

Discussion

Here we report on a large cohort of patients diagnosed with COVID-19 over a 6-week period in a multi-site NHS trust in London. In our cohort, multivariate analysis revealed male gender, increased age, increased frailty and lower platelet count were independently associated with increased risk of ICU admission and/or death within 30 days of COVID-19 diagnosis, while taking antiplatelet medication was associated with a lower risk of poor outcome. Furthermore, within the subset of our cohort with diabetes (96% Type 2 and 4% Type 1), multivariate analysis demonstrated male gender, pre-existing ischaemic heart disease, advancing age and lower platelet count were associated with increased risk of ICU admission and/or death.

In general, patients with diabetes are at increased risk of hospitalisation. Prior to the COVID-19 pandemic, data from the National Diabetes Inpatient Audit indicate the prevalence of diabetes amongst hospital inpatients in England and Wales is 18%²². Using data from a UK primary care database, Barron et al. reported that people with both Type 1 and Type 2 diabetes had multiply-adjusted increased odds of dying in hospital with COVID-19 compared to those without diabetes²³. Our results show that people with diabetes are at increased risk of severe or life threatening COVID-19, although this was driven by its tendency to co-exist with other conditions, particularly ischaemic heart disease. The relative proportions of patients admitted with COVID-19 with Type 1 and Type 2 diabetes were similar to the population we serve, suggesting no difference in susceptibility based on diabetes type.

Hyperglycaemia is a modifiable factor that may influence outcome in COVID-19, especially in people with diabetes. In our cohort, recent HbA1c was not a significant predictor of poor outcome, which is similar to some other cohort studies¹³. In patients with diabetes (and in patients without diabetes), our data demonstrate that blood glucose ≥ 10 mmol/L (at the time of COVID-19 diagnosis and on average during the 72 hours following COVID-19 diagnosis) is associated with increased risk of death/ICU admission. Similar findings have

been reported by groups from France¹³ and China^{12,14}. This association is not sustained on multivariate analysis in our patients with diabetes and there is no prospective study to address whether maintaining blood glucose <10 mmol/L would improve outcomes for patients with diabetes with COVID-19. Furthermore, maintaining blood glucose <10 mmol/L may become even more challenging to achieve as the use of dexamethasone in the management of severe COVID-19 becomes more widespread, following publication of beneficial reports of its use in this context²⁴.

It is unsurprising that diabetes should be associated with a poorer outcome as it is in many infections, often attributed to the relative immunocompromise associated with hyperglycaemia²⁵. It is now well established that patients with more severe manifestations of COVID-19 (including those that need to be escalated to ICU care and those that die) are much more likely to have a diagnosis of diabetes than those who are documented as having a mild form of the infection^{4,23,26}. Some people have recommended that patients with diabetes need to be more actively shielded, and diabetes may be associated with a higher risk of viral infection²⁷. However, it is important to note that here we show that diabetes, in its own right, is not a major factor contributing to the risk of death/ICU admission, but rather its association with other consequences of the metabolic syndrome confers a higher risk of a poor outcome. For instance, all other things being equal, patients (in our cohort) with diabetes have a 33% increased risk of death/ICU admission if they also have ischaemic heart disease.

In line with our observations that it is multimorbidity *per se* and not any particular diagnosis that confers a strong increased risk of poorer outcomes in COVID-19 infection, we show that the CFS is a robust, independent predictor of poor outcome on multivariate analysis. This is consistent with (COVID-19 and non-COVID-19) studies that show that as the CFS increases, the likelihood of mortality increases^{21,28}. However, we have also shown that the CFS is much less useful in younger age groups. We chose death or ICU admission as our primary outcome measure, as this incorporated all patients with severe (life threatening)

COVID-19. Our cohort also included those who, with unfavourable chances of tolerating and surviving invasive ventilation, would not have been admitted to ICU due to pre-existing multimorbidity.

We report a strongly significant and independent risk of death/ICU admission as platelet count decreases. The inverse relationship between platelet count and risk of death/ICU admission with COVID-19 has also been reported by several other studies^{26,29,30}. As microvascular and macrovascular thrombosis is increasingly being reported as a feature of severe COVID-19³¹⁻³³, reduced platelet count may reflect consumptive coagulopathy (d-dimers were significantly higher in the primary outcome group), possibly in conjunction with direct effects on thrombopoiesis or platelet survival. There is no international consensus yet on the use of anticoagulation in COVID-19. We show that patients on antiplatelet drugs were more likely to survive (all other things being equal), even though ischaemic heart disease (the most common indication for their use) was an independent predictor of poorer outcome.

Strengths of our study include a diverse population of patients, and in-depth characterisation, including CFS and numerous pre-hospital and presentation factors. We selected a statistical approach focussed on a primary outcome measure with no selection bias for the multivariate analysis that produced intuitive results, which survived robust sensitivity analysis.

Some of our findings are at odds with other reports. For example, we report no particular association of Black or South Asian ethnicity as an independent risk factor for poorer outcome. However, in 34% of our cohort, ethnicity was reported as mixed, other or unknown, which may have accounted for the disparity between our results and reports that suggest people with non-White ethnicity have poorer outcomes³⁴. Furthermore, in our clinical experience we noted a strong interaction between ethnicity and socioeconomic strata, hence job type – with many lower paid jobs associated with the inability to work from home. In the UK, people of Black and South Asian ethnicities are also more likely to work

in frontline healthcare roles³⁵. Socioeconomic data, including job family, should be included in future analyses. It is worthy of note that patients of Black ethnicity were over-represented in our cohort compared to population levels in the community we serve (Black: 17% in our cohort, 7-12% in the community; and South Asian: 11% in our cohort, 9-12% in the community)³⁶. It remains to be understood to what extent this is a reflection of increased risk of infection due to socioeconomic factors as opposed to other factors.

We were unable to include BMI as a regressor in this dataset as height is not routinely recorded in our Trust. When body weight was included in our multivariate analysis, it did not contribute independently and was removed due to insufficient patients with accurate data. Other studies have concluded that BMI is an important predictor of poorer outcomes, including for patients with diabetes. This concurs with our message that it is not a particular disease *per se* but rather a constellation of factors (typified by the metabolic syndrome) that confers risk. Estimated glomerular filtration rate (eGFR) was also not an independent predictor for poor outcome in patients with diabetes.

Our data suggest that diabetes should not be considered differently to other common co-morbidities in the risk assessment for patients with COVID-19. The tendency for diabetes to cluster with more significant predictors of poor outcome such as ischaemic heart disease is important to recognise, in addition to other independently associated risk factors such as age, male gender and lower platelet count. This study contributes further to understanding the drivers of poor outcomes in patients with diabetes admitted to hospital with COVID-19.

Conclusions

313 This study contributes to the pool of knowledge of the determinants of poor outcomes with
 314 COVID-19. Male gender, ischaemic heart disease, advancing age, multi-morbidity (as
 315 crystallised in the Clinical Frailty Scale) and lower platelet count are important predictors of
 316 poor outcome in patients with severe COVID-19 (both in patients with diabetes and those
 317 without diabetes). Antiplatelet medications confer an advantage. There is no clear
 318 evidence that dysglycaemia drives the increased risk of death/ICU admission amongst
 319 patients with diabetes, but rather the association of diabetes with other common medical
 320 conditions confers excess risk of poor outcomes.

Methods

STUDY SETTING

We performed this retrospective cohort study at Imperial College Healthcare NHS Trust (ICHNT), which includes three hospitals admitting patients with COVID-19 (Charing Cross Hospital, Hammersmith Hospital and St Mary's Hospital). All patients who had a nasopharyngeal swab taken to determine SARS-CoV-2 infection between 9th March 2020 and 22nd April 2020 were identified on an automated search of the laboratories' computer systems. COVID-19 diagnosis was determined by the presence of SARS-CoV-2 infection as evidenced by a positive reverse transcription-polymerase chain reaction (RT-PCR) result from a nasopharyngeal swab. RT-PCR was performed on nasopharyngeal swabs by NorthWest London Pathology staff in the laboratories in the constituent hospitals of ICHNT.

Excluded from data collection were: all patients with negative SARS-CoV-2 swab results, patients who did not have an Emergency Department attendance and/or an inpatient admission within ICHNT, and all patients aged less than 18 years (Figure 1). This study was approved by the ICHNT Clinical Audit Office, was performed in accordance with the Declaration of Helsinki and UK Data Protection legislation. For patients with more than one positive swab result or multiple hospital admissions during the data collection period, the date of the earliest swab result and the most significant hospital admission in terms of COVID-19 severity, respectively, was used for data collection.

DATA COLLECTION

Data collection was performed by physicians working in ICHNT. Hospital numbers of patients with positive swab results were checked against electronic health records held on the ICHNT computer system (Cerner Corporation, Kansas City, USA). Data is uploaded onto Cerner manually by health practitioners and administrators to record and store patient notes, prescribe and dispense medication; as well as store investigation results and clinic

letters. Furthermore, Cerner is connected to the National Health Service (NHS) Spine, which synchronises other data (such as date of death).

Demographic, clinical and biochemical data (on the date of admission/Emergency Department attendance or on the date of the first positive SARS-CoV-2 swab result if the patient had been admitted for ≥ 1 week), as well as outcome data were collected for all eligible patients up to and including 20th June 2020 to ensure there was a minimum of 30 days of follow-up after the date of COVID-19 diagnosis to eliminate the issue of censoring.

Data collected included: demographic and clinical characteristics (age, gender, ethnicity, latest body weight), past medical history, specific comorbidities and medications on admission. Clinical details about diabetes were noted including: classification of diabetes, duration of diabetes and hypoglycaemic medications. A score using the Clinical Frailty Scale (CFS)¹⁷ was assigned to every patient. Haematological and biochemical data for the day of COVID-19 diagnosis included full blood count, routine biochemistry and arterial blood gas results. Average capillary blood glucose values were recorded for the first three days following COVID-19 diagnosis and the most recent HbA1c result (within 6 months) was also recorded.

STATISTICAL ANALYSIS

The composite primary outcome was admission to ICU or death within 30 days of COVID-19 diagnosis, and data on the primary outcome was collected for all patients. This was chosen to capture patients with severe and/or life-threatening COVID-19. Univariate and then unrestricted multivariate logistic regression analyses were performed to look for factors associated with an increased risk of the primary outcome (i.e. death or ICU admission within 30 days of COVID-19 diagnosis). Unlike a Cox proportional hazards approach, this analysis focusses more on “if” a patient gets severely ill rather than survival duration.

The first stage of analysis was descriptive. Quantitative data are expressed as mean $\pm$ SD. Categorical variables were given as percentage (number) of participants. Univariate logistic regression models were used to calculate odds ratios (OR) associated with the primary outcome. Comparison between two groups was analysed using Student's t-tests (normally distributed data) or Mann-Whitney U test (non-normally distributed data) for continuous variables. Comparison of categorical variables was analysed by Fisher's exact test or χ^2 test. A difference with a two-sided $\alpha < 0.05$ was considered statistically significant.

Multivariable logistic regression was applied to assess the independent association of the primary outcome with all the clinical and biological features included in the study. For the top level (unrestricted) analysis only datasets with $<5\%$ missing values were included, leaving a total n number of 716 patients and 37 predictors (variables). No data points were imputed. Data was winsorized (at 1% level) to neutralise the effects of the most extreme values. Following this first step, a regularised regression (Smoothly Clipped Absolute Deviation - SCAD) analysis¹⁸⁻²⁰ was performed to independently account for the over-dimensionality of the unrestricted multivariate. In brief, this sensitivity analysis allows unbiased selection of the most relevant and important predictors and controlling the errors involved in variable selection, without the need to re-estimate the model in a stepwise fashion. Results are presented as the estimate parameter, the p-value of the association and the marginal effect size.

Next, only patients with diabetes were included in multivariate and regularised regression analyses, to look for elements of their clinical presentation that were associated with poorer outcome with COVID-19. Finally, marginal effects for the most significant (independent) risk factors were sub-stratified by age (for the CFS) and the presence or absence of ischaemic heart disease or usage of antiplatelet agents (for platelet counts). All statistical analyses (VS and WD) were performed on GraphPad Prism V8.1 (descriptive statistics) and custom written MaTLAB scripts (multivariate analyses). A detailed description of statistical methods can be found in the Supplementary Methods.

400 **Acknowledgments**

401 The Section of Endocrinology and Investigative Medicine is funded by grants from the
 402 MRC, BBSRC, NIHR and is supported by the NIHR Biomedical Research Centre Funding
 403 Scheme. The views expressed are those of the authors and not necessarily those of the
 404 MRC, BBSRC, the NHS, the NIHR or the Department of Health and Social Care. CI is
 405 funded by an Imperial-BRC IPPRF Fellowship, JK is funded by an NIHR Doctoral Research
 406 Fellowship (DRF-2017-10-042), SM is funded by a Future Leaders Mentorship Award from
 407 the European Association for the Study of Diabetes, TT is funded by the MRC and NIHR,
 408 VS is funded by a Harry Keen Diabetes UK Fellowship.

409 **Author Contributions**

410 Conceptualization, CI, TT, NH and VS.; Methodology, CI, AA, DH, TT, NH and VS;
 411 Investigation, CI, AA, WY, OI, JK, RS, EW, CS, NA, HB, NB, SB, ML, SP, ES, ET, AQ, MA,
 412 DH, NO, VB, SM, TT, NH and VS.; Formal analysis, WD, VS; Data curation, CI, AA, SM,
 413 TT, NH and VS; Writing—original draft preparation, CI and VS.; Writing—review and
 414 editing, CI, WD, AA, WY, OI, JK, RS, EW, CS, NA, HB, NB, SB, ML, SP, ES, ET, AQ, MA,
 415 DH, NO, VB, SM, TT, NH and VS.; Visualization, CI, WD and VS. All authors have read
 416 and agreed to the published version of the manuscript.

417 **Competing Interests**

418 The authors declare no conflict of interest.

419 References

- 420 1 Office for National Statistics. Deaths registered weekly in England and Wales, provisional:
421 week ending 26 June 2020. (2020).
422 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/weekending26june2020)
423 [deathsregisteredweeklyinenglandandwalesprovisional/weekending26june2020](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/weekending26june2020). Accessed on
424 07/07/2020.
- 425 2 Academy of Medical Sciences. Preparing for a challenging winter 2020/21. (2020).
426 <https://acmedsci.ac.uk/file-download/51353957>. Accessed on 21/07/2020.
- 427 3 Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus
428 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the
429 Chinese Center for Disease Control and Prevention. *JAMA*, doi:10.1001/jama.2020.2648
430 (2020).
- 431 4 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*
432 **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
- 433 5 Yang, X. *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2
434 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet*
435 *Respir Med* **8**, 475-481, doi:10.1016/S2213-2600(20)30079-5 (2020).
- 436 6 Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
437 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507-513,
438 doi:10.1016/S0140-6736(20)30211-7 (2020).
- 439 7 Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
440 China. *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- 441 8 Public Health England. Diabetes Prevalence and Risk. (2020).
442 [https://fingertips.phe.org.uk/profile/diabetes-](https://fingertips.phe.org.uk/profile/diabetes-ft/data#page/0/gid/1938133138/pat/44/par/E40000003/ati/154/are/E38000070/cid/4/tbm/1/page-options/oww-do-0)
443 [ft/data#page/0/gid/1938133138/pat/44/par/E40000003/ati/154/are/E38000070/cid/4/tbm/1/page-](https://fingertips.phe.org.uk/profile/diabetes-ft/data#page/0/gid/1938133138/pat/44/par/E40000003/ati/154/are/E38000070/cid/4/tbm/1/page-options/oww-do-0)
444 [options/oww-do-0](https://fingertips.phe.org.uk/profile/diabetes-ft/data#page/0/gid/1938133138/pat/44/par/E40000003/ati/154/are/E38000070/cid/4/tbm/1/page-options/oww-do-0). Accessed on 12/07/2020.
- 445 9 Booth, C. M. *et al.* Clinical features and short-term outcomes of 144 patients with SARS in
446 the greater Toronto area. *JAMA* **289**, 2801-2809, doi:10.1001/jama.289.21.JOC30885
447 (2003).
- 448 10 Alqahtani, F. Y. *et al.* Prevalence of comorbidities in cases of Middle East respiratory
449 syndrome coronavirus: a retrospective study. *Epidemiol Infect*, 1-5,
450 doi:10.1017/S0950268818002923 (2018).
- 451 11 Joensen, L. E. *et al.* Diabetes and COVID-19: psychosocial consequences of the COVID-19
452 pandemic in people with diabetes in Denmark-what characterizes people with high levels
453 of COVID-19-related worries? *Diabet Med* **37**, 1146-1154, doi:10.1111/dme.14319 (2020).
- 454 12 Zhu, L. *et al.* Association of Blood Glucose Control and Outcomes in Patients with COVID-19
455 and Pre-existing Type 2 Diabetes. *Cell Metab* **31**, 1068-1077 e1063,
456 doi:10.1016/j.cmet.2020.04.021 (2020).
- 457 13 Cariou, B. *et al.* Phenotypic characteristics and prognosis of inpatients with COVID-19 and
458 diabetes: the CORONADO study. *Diabetologia*, doi:10.1007/s00125-020-05180-x (2020).
- 459 14 Wang, S. *et al.* Fasting blood glucose at admission is an independent predictor for 28-day
460 mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre
461 retrospective study. *Diabetologia*, doi:10.1007/s00125-020-05209-1 (2020).
- 462 15 Li, J. *et al.* COVID-19 infection may cause ketosis and ketoacidosis. *Diabetes Obes Metab*,
463 doi:10.1111/dom.14057 (2020).
- 464 16 Armeni, E. *et al.* Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a
465 retrospective case series. *Lancet Diabetes Endocrinol*, doi:10.1016/S2213-8587(20)30221-7
466 (2020).
- 467 17 Rockwood, K. *et al.* A global clinical measure of fitness and frailty in elderly people. *CMAJ*
468 **173**, 489-495, doi:10.1503/cmaj.050051 (2005).

469 18 Fan, J. & Li, R. Variable selection via nonconcave penalized likelihood and its oracle
470 properties. *Journal of the American Statistical Association* **96**, 1348-1360 (2001).
471 19 Liu, X., Song, X., Xie, S. & Zhou, Y. Variable selection for frailty transformation models with
472 application to diabetic complications. *Canadian Journal of Applied Statistics* **44**, 375-394
473 (2016).
474 20 Wang, J. H., Pan, C. H., Chang, I. S. & Hsiung, C. A. Penalized full likelihood approach to
475 variable selection for Cox's regression model under nested case-control sampling. *Lifetime*
476 *Data Anal* **26**, 292-314, doi:10.1007/s10985-019-09475-z (2020).
477 21 Hewitt, J. *et al.* The effect of frailty on survival in patients with COVID-19 (COPE): a
478 multicentre, European, observational cohort study. *Lancet Public Health*,
479 doi:10.1016/S2468-2667(20)30146-8 (2020).
480 22 NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2017. (2018).
481 [https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-audit/national-diabetes-inpatient-audit-nadia-2017)
482 [audit/national-diabetes-inpatient-audit-nadia-2017](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-audit/national-diabetes-inpatient-audit-nadia-2017). Accessed on 21/07/2020.
483 23 Barron, E. *et al.* Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a
484 whole population study. (2020). [https://www.england.nhs.uk/wp-](https://www.england.nhs.uk/wp-content/uploads/2020/05/valabhji-COVID-19-and-Diabetes-Paper-1.pdf)
485 [content/uploads/2020/05/valabhji-COVID-19-and-Diabetes-Paper-1.pdf](https://www.england.nhs.uk/wp-content/uploads/2020/05/valabhji-COVID-19-and-Diabetes-Paper-1.pdf). Accessed on 13/07/2020.
486 24 Horby, P. *et al.* Effect of Dexamethasone in Hospitalized Patients with COVID-19:
487 Preliminary Report. (2020). Preprint at
488 <https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1>. Accessed on 13/07/2020.
489 25 Clement, S. *et al.* Management of diabetes and hyperglycemia in hospitals. *Diabetes Care*
490 **27**, 553-591, doi:10.2337/diacare.27.2.553 (2004).
491 26 Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-
492 19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062,
493 doi:10.1016/S0140-6736(20)30566-3 (2020).
494 27 Carey, I. M. *et al.* Risk of Infection in Type 1 and Type 2 Diabetes Compared With the
495 General Population: A Matched Cohort Study. *Diabetes Care* **41**, 513-521,
496 doi:10.2337/dc17-2131 (2018).
497 28 Chong, E., Chan, M., Tan, H. N. & Lim, W. S. COVID-19: Use of the Clinical Frailty Scale for
498 Critical Care Decisions. *J Am Geriatr Soc* **68**, E30-E32, doi:10.1111/jgs.16528 (2020).
499 29 Tang, N. *et al.* Anticoagulant treatment is associated with decreased mortality in severe
500 coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* **18**, 1094-1099,
501 doi:10.1111/jth.14817 (2020).
502 30 Lippi, G., Plebani, M. & Henry, B. M. Thrombocytopenia is associated with severe
503 coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta* **506**, 145-
504 148, doi:10.1016/j.cca.2020.03.022 (2020).
505 31 Magro, C. *et al.* Complement associated microvascular injury and thrombosis in the
506 pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res* **220**, 1-13,
507 doi:10.1016/j.trsl.2020.04.007 (2020).
508 32 Middeldorp, S. *et al.* Incidence of venous thromboembolism in hospitalized patients with
509 COVID-19. *J Thromb Haemost*, doi:10.1111/jth.14888 (2020).
510 33 Poissy, J. *et al.* Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased
511 Prevalence. *Circulation*, doi:10.1161/CIRCULATIONAHA.120.047430 (2020).
512 34 Williamson, E. J. *et al.* OpenSAFELY: factors associated with COVID-19 death in 17 million
513 patients. *Nature*, doi:10.1038/s41586-020-2521-4 (2020).
514 35 UK Government. Ethnicity facts and figures. (2020). [https://www.ethnicity-facts-](https://www.ethnicity-facts-figures.service.gov.uk/)
515 [figures.service.gov.uk/](https://www.ethnicity-facts-figures.service.gov.uk/) Accessed on 23/07/2020.
516 36 Office for National Statistics. 2011 Census. (2015).
517 [https://webarchive.nationalarchives.gov.uk/20160107072059/http://www.ons.gov.uk/ons/rel/census/20](https://webarchive.nationalarchives.gov.uk/20160107072059/http://www.ons.gov.uk/ons/rel/census/2011-census/index.html)
518 [11-census/index.html](https://webarchive.nationalarchives.gov.uk/20160107072059/http://www.ons.gov.uk/ons/rel/census/2011-census/index.html). Accessed on 23/07/2020.

519 **Figure Legends**

520 **Figure 1:** All 2442 patients who had nasopharyngeal swabs taken for reverse
521 transcriptase polymerase chain reaction (RT-PCR) to detect the presence of SARS-CoV-2
522 (and diagnose COVID-19) between 9th March 2020 and 22nd April 2020 were assessed for
523 eligibility. 1350 patients with negative swab results were excluded. Of 1092 patients with
524 positive swab results, 203 were excluded (as they did not have an Emergency Department
525 attendance and/or inpatient hospital admission, or they were aged less than 18 years); and
526 889 patients were included in the statistical analyses. eGFR = estimated glomerular
527 filtration rate.

528 **Figure 2:** On unbiased univariate analysis of 798 patients admitted with COVID-19, the
529 Clinical Frailty Scale (CFS) was a significant independent predictor of poor outcomes, with
530 a marginal effect size of 3% for every increase in score between 1-9 (see Table 3). We
531 stratified the marginal effect by age bands. There was a trend (Figure 2a) for the marginal
532 effect of the CFS on the primary outcome to be greater in the older population. Similarly,
533 there was a trend for the independent marginal effect of platelet count on the primary
534 outcome to increase with age (Figure 2b), but there was no interaction with the marginal
535 effect size of platelet count on outcomes as stratified by the use of antiplatelet drugs (data
536 not shown).

537 **Table 1 – Demographic and Clinical Features of 889 Patients Treated for COVID-19**
 538 **Patients in ICHNT Between March and April 2020 (Univariate Analysis for primary**
 539 **outcome of death or Intensive Care Unit admission within 30 days of swab positive**
 540 **diagnosis).**

WHOLE COHORT						
Clinical feature		Number of patients with data	Prevalence (n)	Odds ratio of primary outcome (OR)	95% confidence interval (CI)	p-value
Female		889	40% (355)	0.69	0.52 to 0.91	0.01
Age (years)		889				
	18-49		18% (164)	0.40	0.24 to 0.67	<0.0001
	50-59		18% (157)	1	REFERENCE	
	60-69		17% (147)	1.11	0.74 to 1.84	0.55
	70-79		22% (193)	1.33	0.86 to 2.03	0.23
	>80		26% (228)	1.41	0.92 to 2.15	0.21
Weight (kg)		693				
	<80		61% (420)	1	REFERENCE	
	≥80		39% (273)	1.15	0.84 to 1.57	0.42
Ethnicity		865				
	White		38% (327)	1	REFERENCE	
	Black		17% (146)	1.21	0.81 to 1.81	0.40
	South Asian		11% (97)	1.04	0.64 to 1.66	>0.9
	All non-White		62% (538)	1.35	1.01 to 1.81	0.04
Smoking status		484				
	Current/ex-smoker		189	1	REFERENCE	
	Never smoked		295	1.38	0.93 to 2.03	0.11
Co-morbidities		889		<i>OR (co-morbidity vs without co-morbidity)</i>		
	Hypertension		47% (418)	2.41	1.82 to 3.20	<0.001
	Hyperlipidaemia		33% (296)	1.56	1.16 to 2.08	0.04
	Ischaemic heart disease		16% (144)	2.25	1.58 to 3.23	<0.001
	Stroke		13% (120)	0.98	0.66 to 1.46	>0.9
	Heart failure		10% (87)	2.49	1.60 to 3.85	<0.001
	COPD		9% (80)	1.12	0.71 to 1.81	0.63
	Active cancer		9% (79)	1.15	0.72 to 1.86	0.62
Pre-admission medications		889		<i>OR (taking specified medication vs not taking the medication)</i>		
	Statin		42% (373)	1.49	1.13 to 1.97	0.006
	Anti-platelet drug		23% (204)		0.92 to 1.75	0.14
	ACE inhibitor		17% (151)	1.57	1.10 to 2.23	0.013
	Angiotensin II receptor blocker		13% (116)	1.43	0.95 to 2.12	0.09

CFS Score (1-9)		756				
	1 - 2		40% (300)	1	REFERENCE	
	3 - 4		32% (242)	1.50	1.05 to 2.15	0.03
	5 - 6		15% (110)	1.75	1.20 to 2.52	0.003
	≥7		13% (104)	2.34	1.46 to 3.75	0.0004
eGFR at time of COVID-19 diagnosis (mL/kg/min)		880				
	>90		27% (240)	1	REFERENCE	
	60 - 90		31% (269)	1.60	1.06 to 2.41	0.02
	45 - 59		11% (95)	2.35	1.40 to 3.91	0.001
	30 - 44		10% (93)	4.28	2.60 to 7.21	<0.0001
	15 - 29		9% (78)	3.02	1.78 to 5.16	<0.0001
	<15		12% (105)	4.19	2.56 to 6.78	<0.0001
Glucose at time of COVID-19 diagnosis		652				
<i>WHOLE COHORT</i>	<10 mmol/L		78% (508)	1	REFERENCE	
	≥10 mmol/L		22% (144)	2.04	1.39 to 2.95	0.0002
		394				
<i>PATIENTS WITHOUT DIABETES</i>	<10 mmol/L		94% (369)	1	REFERENCE	
	≥10 mmol/L		6% (25)	3.56	1.60 to 8.62	0.004
PATIENTS WITH DIABETES						
Diabetes diagnosis		889				
	Patients without diabetes		62% (552)	1	REFERENCE	
	Patients with diabetes		38% (337)	1.68	1.27 to 2.12	0.0003
Type of diabetes		337				
	Type 2		96% (324)	1	REFERENCE	
	Type 1		4% (13)	0.37	0.11 to 1.27	0.16
Duration of diabetes		189				
	<10 years		47% (88)	1	REFERENCE	
	≥10 years		53% (101)	1.82	1.03 to 3.34	0.054
Diabetes medication at time of COVID-19 diagnosis		337		<i>OR (taking specified medication vs not taking the medication)</i>		
	Insulin		31% (108)	0.88	0.55 to 1.42	0.64
	GLP-1RA		1% (5)	0.52	0.09 to 2.60	0.66
	Metformin		49% (169)	1.14	0.74 to 1.76	0.58

	Sulphonylurea		22% (74)	0.85	0.50 to 1.45	0.59
	SGLT2 inhibitor		7% (24)	0.66	0.30 to 1.52	0.40
	DPPIV inhibitor		27% (93)	1.27	0.79 to 2.05	0.39
	Total number of diabetes medications					
	0		18% (57)	1	REFERENCE	
	1		41% (139)			0.75
	2		28% (96)			>0.9
	≥3		13% (45)			>0.9
HbA1c		240				
	<58 mmol/mol		47% (112)	1	REFERENCE	
	≥58 mmol/mol		53% (128)	1.44	0.85 to 2.39	0.19
Glucose at time of COVID-19 diagnosis		323				
	<10 mmol/L		56% (181)	1	REFERENCE	
	≥10 mmol/L		44% (142)	1.65	1.07 to 2.56	0.03
Average CBG in 1 st 72hr after COVID-19 diagnosis		306				
	<10 mmol/L		64% (197)	1	REFERENCE	
	≥10 mmol/L		36% (109)	1.93	1.22 to 3.11	0.008

541

542 **Table 1:** 889 patients with confirmed (swab positive) COVID-19 were analysed and
543 univariate odds ratios (OR) against a defined comparator are provided for our predefined
544 primary outcome of death or ICU admission within 30 days of diagnosis. ACE inhibitor =
545 angiotensin converting enzyme inhibitor, CBG = capillary blood glucose, CFS = Clinical
546 Frailty Scale, COPD = Chronic obstructive pulmonary disease, DPPIV inhibitor = dipeptidyl
547 peptidase-IV inhibitor, eGFR = estimated glomerular filtration rate, GLP-1RA = glucagon-
548 like peptide-1 receptor agonist, HbA1c = glycated haemoglobin, SGLT2 inhibitor = sodium-
549 glucose co-transporter-2 inhibitor. Significant p-values for odds ratios using Fishers' exact
550 test are shown in **bold**.

Table 2 - Biochemical Measurements and Clinical Observations for 889 patients admitted with COVID-19.

	Measurement at time of diagnosis	Primary outcome (died/ICU admission within 30 days)			Survived/no ICU admission			p-value (primary outcome vs survived/no ICU)	Patients without diabetes mellitus (no DM)			Patients with diabetes mellitus (DM)			p-value (no DM vs DM)
		n	mean	SD	n	mean	SD		n	mean	SD	n	mean	SD	
Arterial Blood Gas (ABG) measurement	FiO2 recorded on ABG	260	48.70	26.68	403	29.81	18.2	<0.0001	403	36.4	23.2	260	38.51	24.64	0.2867
	Lactate (mmol/L)	260	1.83	1.78	403	1.536	1.028	0.0077	402	1.58	1.4	261	1.765	1.347	0.0031
	pCO2 (kPa)	258	4.93	1.36	402	5.078	2.746	0.4618	401	4.96	1.28	259	5.117	3.321	0.8276
	pO2 (kPa)	255	8.81	5.97	397	8.208	5.596	0.1448	397	8.27	5.45	255	8.71	6.183	0.5349
	Base excess (mmol/L)	256	-0.41	17.52	397	-0.37	4.953	0.1049	397	0.0348	5.05	256	-	6.781	0.0003
	pH	259	7.41	0.097	401	7.421	0.08202	0.222	401	7.43	0.0813	259	7.401	0.09645	0.001
	Bicarbonate (mmol/L)	256	23.28	5.69	400	24.05	4.415	0.0962	398	24.3	4.69	258	22.83	5.233	0.0022
Laboratory results	WCC (x10 ⁹ /L)	320	8.61	4.09	561	7.95	4.635	0.0015	545	8.12	4.61	337	8.308	4.194	0.276
	Hb (g/L)	320	125.70	23.15	562	129.3	20.96	0.0264	546	130	22.1	337	124.8	21.09	0.0006
	Platelet count (x10 ⁹ /L)	319	218.20	104.70	562	238.4	105.5	0.0024	545	232	111	337	230.4	95.88	0.6622
	Neutrophils (x10 ⁹ /L)	318	7.42	7.22	562	6.346	8.549	<0.0001	545	6.28	4.18	336	7.472	11.98	0.0805
	Lymphocytes (x10 ⁹ /L)	317	0.98	0.997	562	1.219	1.206	<0.0001	545	1.17	1.34	335	1.079	0.7064	0.8785
	D-dimers (ng/ml)	221	3895	5292	332	2445	3671	<0.0001	336	2556	3714	218	3742	5305	0.0096
	Ferritin (ng/mL)	233	2122	5214	358	1313	1824	<0.0001	358	1553	2368	234	1751	4896	0.6944
	Na (mmol/L)	320	138.30	6.231	560	137	7.424	0.043	544	138	7.62	337	136.9	5.944	0.0008
	K (mmol/L)	309	4.33	0.75	534	4.213	0.5569	0.0783	524	4.18	0.603	320	4.378	0.6716	<0.0001
	eGFR (mL/min)	319	51.14	29.67	560	65.66	27.47	<0.0001	544	67	26.4	336	49.64	30.14	<0.0001
	eGFR pre-COVID19	236	60.38	29.93	457	72.64	46.48	<0.0001	411	75.4	47.2	283	58.38	30.34	<0.0001

	baseline (mL/min)														
	ALT (U/L)	295	53.08	155.10	515	39.28	57.06	0.6581	494	46.7	113	317	40.54	88.75	0.0657
	CRP (mg/L)	314	156.9	104.40	542	94.33	88.34	<0.0001	527	106	94	330	135.8	104.3	<0.0001
	CK (U/L)	206	641.9	1184	311	391.8	1179	<0.0001	307	510	1320	211	464.5	960.5	0.6773
	LDH (U/L)	186	602.5	626	291	398.8	230.2	<0.0001	293	480	413	185	475.4	482.1	0.9935
	BNP (pg/mL)	184	423.1	1451	267	192.2	762.7	<0.0001	279	201	754	173	422.4	1489	0.0688
	Procalcitonin (ng/mL)	33	20.5	69.04	49	0.538	1.527	<0.0001	55	8.96	49.4	27	7.774	33.11	0.0469
	HbA1c - most recent (mmol/mol)	160	54.18	20.28	274	53.27	21.22	0.4003	194	39.8	7.14	240	64.73	21.66	<0.0001
Glucose	CBG – at time of COVID19 diagnosis	269	10.04	5.54	416	8.312	5.398	<0.0001	375	6.97	2.07	311	11.43	7.145	<0.0001
	Average CBG in first 72hr of COVID-19 diagnosis	244	9.256	3.59	332	7.795	3.187	<0.0001	273	6.9	1.77	303	9.776	3.969	<0.0001
Clinical observations at diagnosis	Temperature (°C)	311	37.38	1.19	558	37.26	1.016	0.0441	537	37.3	1.07	333	37.27	1.101	0.7922
	Respiratory Rate (Breaths per minute)	312	25.54	8.82	556	22.03	6.049	<0.0001	539	23.3	7.41	330	23.34	7.278	0.6356
	Heart Rate (beats per minute)	314	95.91	20.34	558	92.42	18.37	0.0093	541	93	19.1	332	94.72	19.24	0.256
	Systolic BP (mmHg)	316	134.8	27.49	560	131.2	23.74	0.0452	543	130	24.5	334	136.1	25.99	0.0011
	Diastolic BP (mmHg)	316	73.53	16.06	559	75.67	13.81	0.0321	542	75.9	14.5	334	73.24	14.84	0.0053
	NEWS at arrival	300	6	3.44	540	4.05	3.642	<0.0001	523	4.63	3.95	321	4.938	3.234	0.0515

Table 2: Unadjusted comparisons are shown for patients who met the primary outcome (death or ICU admission within 30 days of diagnosis) against those who survived and did not have an ICU admission (columns 3-5); and for patients with diabetes against those without (columns 6-8). n = number of patients for whom that data set is available. Note the total number of patients arriving at the primary outcome was 323 and the total number of patients

with diabetes mellitus (DM) was 327. ABG = arterial blood gas, ALT = alanine aminotransferase, BNP = brain natriuretic peptide, BP = blood pressure, CBG = capillary blood glucose, CRP = C-reactive protein, CK = creatinine kinase, eGFR = estimated glomerular filtration rate, FiO2 = fraction of inspired oxygen, Hb = haemoglobin, HbA1c = glycated haemoglobin, K = potassium, LDH = lactate dehydrogenase, Na = sodium, NEWS = National Early Warning Score, WCC = white cell count.

Table 3 - Unbiased Multivariate Logistic Regression Analysis of 37 Regressors (variables) against the Primary Outcome of Death/ICU Admission within 30 Days of COVID-19 Diagnosis (n=719 patients)

Regressor	Estimate	SE	p-value	Marginal Effect (%)
Age	0.029	0.011	0.005	0.5
Male gender	0.553	0.256	0.031	9.3
Ethnicity - South Asian	-0.321	0.441	0.466	-5.4
Ethnicity - Black	-0.296	0.360	0.411	-5.0
Ethnicity - White	-0.179	0.272	0.510	-3.0
Diabetes mellitus	0.099	0.265	0.709	1.7
Stroke	-0.457	0.348	0.189	-7.7
Hyperlipidaemia	0.117	0.277	0.673	2.0
Ischaemic heart disease	0.596	0.364	0.102	10.1
Heart Failure	0.046	0.408	0.910	0.8
Hypertension	0.207	0.285	0.468	3.5
Chronic obstructive pulmonary disease	-0.051	0.384	0.893	-0.9
Active cancer	-0.135	0.428	0.752	-2.3
Statin	-0.310	0.288	0.282	-5.2
Angiotensin converting enzyme inhibitor	0.351	0.329	0.285	5.9
Angiotensin II receptor blocker	0.145	0.366	0.691	2.5
Antiplatelet drug	-0.616	0.319	0.053	-10.4
Clinical Frailty Scale	0.183	0.078	0.019	3.1
White cell count	0.031	0.085	0.720	0.5
Haemoglobin	-0.008	0.006	0.182	-0.1
Platelet count	-0.004	0.001	0.001	-0.1
Neutrophils	0.009	0.086	0.920	0.1
Lymphocytes	-0.011	0.229	0.963	-0.2
Serum sodium	0.072	0.023	0.002[#]	1.2
Serum potassium	0.202	0.194	0.300	3.4
eGFR at diagnosis	-0.006	0.005	0.287	-0.1
C-reactive protein	0.002	0.001	0.132	0.0
Temperature	-0.012	0.113	0.913	-0.2
Respiratory rate	0.034	0.021	0.103	0.6
Heart rate	0.006	0.008	0.453	0.1
Systolic blood pressure	0.010	0.006	0.088	0.2
Diastolic blood pressure	-0.002	0.010	0.831	0.0
National Early Warning Score	-0.015	0.055	0.790	-0.2
Inspired oxygen delivered at diagnosis	-0.012	0.006	0.046	-0.2
Oxygen saturations at diagnosis	-0.032	0.018	0.079	-0.5
Maximum inspired oxygen required during admission	0.068	0.007	<0.0001	1.2

Table 3: This is an unselected multivariate logistic (Logit) analysis of all variables that were collected for patients admitted with swab positive COVID-19. 719 patients are included with 37 variables – with the only exclusions being those patients/variables for which ≥5% data points were unknown. For categorical variables, a positive “estimate” indicates an increased risk of the primary outcome (death or ICU admission) with that variable present, and a negative estimate indicates a reduced risk of the primary outcome if

that variable is present. The p-value is a measure of the confidence of that given variable being an independent predictor of the primary outcome corrected for all of the other regressors listed. For continuous variables, a positive “estimate” indicates an increasing risk of the primary outcome as the variable increases. Since in logistic regressions estimated coefficients cannot be interpreted as a measure of the contribution of the effect, we have also calculated marginal effects. A positive marginal effect indicates that an increase in that variable (as defined in Table 2) is associated with a fully adjusted increased risk of the primary outcome. The converse applies for negative marginal effects. For categorical variables, the marginal effect indicates the percentage increased risk of the primary outcome, if that variable exists. So, for example, all other variables being equal, men have a 9.3% increased risk of death or ICU admission than women. eGFR = estimated glomerular filtration rate. [#]The effect of serum sodium was skewed by patients with serum sodium >145 mmol/L.

Table 4 - Unbiased Multivariate Logistic Regression Analysis of 42 Regressors (variables) against the Primary Outcome of Death/ICU Admission within 30 Days of COVID-19 Diagnosis in patients with Diabetes Mellitus (n=268 patients)

Regressor	Estimate	SE	p-value	Marginal Effect (%)
Age	0.059	0.019	0.001	1.3
Male gender	0.827	0.453	0.068	17.9
Ethnicity - South Asian	-1.352	0.736	0.066	-29.2
Ethnicity - Black	0.216	0.578	0.709	4.7
Ethnicity - White	-0.091	0.508	0.858	-2.0
Type 1 Diabetes	0.993	1.135	0.382	21.5
Active Foot Disease	0.075	0.839	0.929	1.6
Stroke	0.338	0.523	0.519	7.3
Hyperlipidaemia	-0.503	0.447	0.261	-10.9
Ischaemic Heart Disease	1.547	0.569	0.007	33.4
Heart Failure	-0.956	0.613	0.119	-20.7
Hypertension	-0.101	0.504	0.841	-2.2
COPD	-0.499	0.661	0.450	-10.8
Active Cancer	-0.383	0.727	0.598	-8.3
Insulin	0.228	0.992	0.818	4.9
GLP-1 mimetic	1.040	1.755	0.553	22.5
Metformin	-0.064	0.918	0.944	-1.4
Sulphonylurea	0.475	0.991	0.632	10.3
DPP4 inhibitor	-0.825	0.935	0.378	-17.8
Total number of diabetic medications	0.137	0.800	0.864	3.0
Statin	-0.105	0.504	0.835	-2.3
ACE inhibitor	0.536	0.513	0.297	11.6
ARB	0.200	0.529	0.705	4.3
Antiplatelet drug	-0.735	0.486	0.130	-15.9
White Cell Count	-0.112	0.146	0.442	-2.4
Hb	-0.018	0.012	0.130	-0.4
Platelet count	-0.009	0.003	0.001	-0.2
Neutrophils	0.123	0.140	0.376	2.7
Lymphocytes	0.093	0.406	0.819	2.0
Serum sodium	0.077	0.039	0.050	1.7
eGFR on diagnosis	-0.012	0.010	0.224	-0.3
CRP	0.002	0.002	0.536	0.0
CBG on diagnosis	0.034	0.038	0.369	0.7
Temperature	0.017	0.206	0.935	0.4
Respiratory rate on diagnosis	0.047	0.041	0.252	1.0
Heart Rate on diagnosis	-0.004	0.014	0.774	-0.1
Systolic Blood Pressure	0.003	0.010	0.793	0.1
Diastolic Blood Pressure	0.015	0.017	0.391	0.3
NEWS score at diagnosis	-0.001	0.110	0.990	0.0
Inspired Oxygen delivered at diagnosis	0.000	0.011	0.974	0.0
Oxygen saturations at diagnosis	0.020	0.036	0.575	0.4
Maximum inspired oxygen required	0.072	0.012	<0.0001	1.6

Table 4: This is an unselected multivariate logistic (Logit) analysis of all variables that were collected for patients admitted with swab positive COVID-19 who had diabetes mellitus, as applied to the primary outcome of death or ICU admission within 30 days. 268 patients are included with 42 variables – with the only exclusions being those patients/variables for which $\geq 5\%$ data points were unknown. For this reason, HbA1C is not included as a regressor as it would have reduced the number of patients included to 168 – although of note in that regression, HbA1c did not survive multiple correction (and neither did body weight). For categorical variables, a positive “estimate” indicates an increased risk of the primary outcome (death or ICU admission) with that variable present, and a negative estimate indicates a reduced risk of the primary outcome if that variable is present. The p-value is a measure of the confidence of that variable being an independent predictor of the primary outcome corrected for all of the other regressors listed. For continuous variables, a positive “estimate” indicates an increasing risk of the primary outcome as the variable increases. Since in logistic regressions estimated coefficients cannot be interpreted as a measure of the contribution of the effect, we have also calculated marginal effects along with their standard errors. A positive marginal effect indicates that an increase in that variable (as defined in Table 2) is associated with a fully adjusted increased risk of the primary outcome. The converse applies for negative marginal effects. For categorical variables, the marginal effect indicates that percentage increased risk of the primary outcome, if that variable exists. So, for example, patients with diabetes (all other things being equal) have a 33% increased risk of death/ICU if they have ischaemic heart disease. eGFR = estimated glomerular filtration rate.

Figure 2

a Marginal Effect of CFS on Primary Outcome stratified by Age

b Marginal Effect of Platelets on Primary Outcome Stratified by Age